Tandem Diabetes Care Inc
Закрыт
СекторЗдравоохранение
15.17 -2.44
Обзор
Изменение цены акций
24 ч
Мин.
15.05
Макс.
15.89
Доход | -20M -20M |
|---|---|
Продажи | -43M 247M |
Прибыль на акцию | -0.3 |
Рентабельность продаж | -8.249 |
Сотрудники | 2,500 |
EBITDA | -25M -14M |
Рекомендации | Покупка |
|---|---|
Прогноз на 12 месяцев | +88.12% upside |
Рыночная капитализация | -305M 1.1B |
|---|---|
Предыдущая цена открытия | 17.61 |
Предыдущая цена закрытия | 15.17 |
Tandem Diabetes Care Inc График
Прошлые результаты не являются надежным индикатором будущих результатов.
Связанные новости
Сравнение c конкурентами
Изменение цены
Tandem Diabetes Care Inc Прогноз
Целевая цена
By TipRanks
88.12% рост
Прогноз на 12 месяцев
Средняя 30.57 USD 88.12%
Максимум 55 USD
Минимум 15.5 USD
Основано на мнении 16 аналитиков Wall Street, спрогнозировавших целевые цены для Tandem Diabetes Care Inc на следующие 12 месяцев – Данные за последние 3 месяца.
Финансовые показатели
$
О компании Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.